- Home
- ETON vs RGC Comparison
ETON vs RGC Comparison
Compare ETON & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- RGC
- Stock Information
- Founded
- ETON 2017
- RGC 2014
- Country
- ETON United States
- RGC Hong Kong
- Employees
- ETON N/A
- RGC N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- RGC Medicinal Chemicals and Botanical Products
- Sector
- ETON Health Care
- RGC Health Care
- Exchange
- ETON Nasdaq
- RGC Nasdaq
- Market Cap
- ETON 428.5M
- RGC 377.5M
- IPO Year
- ETON 2018
- RGC 2021
- Fundamental
- Price
- ETON $16.84
- RGC $684.84
- Analyst Decision
- ETON Strong Buy
- RGC
- Analyst Count
- ETON 3
- RGC 0
- Target Price
- ETON $29.67
- RGC N/A
- AVG Volume (30 Days)
- ETON 440.2K
- RGC 49.9K
- Earning Date
- ETON 05-13-2025
- RGC 06-20-2025
- Dividend Yield
- ETON N/A
- RGC N/A
- EPS Growth
- ETON N/A
- RGC N/A
- EPS
- ETON N/A
- RGC N/A
- Revenue
- ETON $48,327,000.00
- RGC N/A
- Revenue This Year
- ETON $103.21
- RGC N/A
- Revenue Next Year
- ETON $51.34
- RGC N/A
- P/E Ratio
- ETON N/A
- RGC N/A
- Revenue Growth
- ETON 40.88
- RGC N/A
- 52 Week Low
- ETON $3.18
- RGC $3.03
- 52 Week High
- ETON $21.48
- RGC $950.00
- Technical
- Relative Strength Index (RSI)
- ETON 42.38
- RGC 63.54
- Support Level
- ETON $19.56
- RGC $602.01
- Resistance Level
- ETON $19.35
- RGC $560.00
- Average True Range (ATR)
- ETON 1.07
- RGC 127.37
- MACD
- ETON -0.47
- RGC 1.55
- Stochastic Oscillator
- ETON 6.78
- RGC 59.21
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.